Cutaneous vasculitis induced by risedronate

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 63, Issue 10, 2008, Pages 1405-

  Belhadjali, H ^a   Slim, R ^b   Aouam, K ^b   Youssef, M ^b   Zili, J ^b  

^a FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^b NONE

Author keywords

Adverse drug reaction; Biphosphonates; Cutaneous vasculitis; Risedronate

Indexed keywords

RISEDRONIC ACID;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; LABORATORY TEST; LEUKOCYTOCLASTIC VASCULITIS; PHYSICAL EXAMINATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SKIN BIOPSY; VASCULITIC RASH;

AGED; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; HUMANS; SKIN DISEASES, VASCULAR; VASCULITIS;

EID: 51349132603     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2008.01836.x     Document Type: Article

References (8)

1. Umland EM, Boyce EG. Risedronate: a new oral bisphosphonate. Clin Ther 2001 23 : 1409 1421.
2. Barrera BA, Wilton L, Harris S, Shakir SA. Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. Osteoporos Int 2005 16 : 1989 1998.
3. Anastasilakis AD, Goulis DG, Kita M, Avramidis A. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases. Hormones (Athens) 2007 6 : 233 241.
4. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol 2003 48 : 311 340.
5. Kontoleon P, Ilias I, Stavropoulos PG, Papapetrou PD. Urticaria after administration of alendronate. Acta Derm Venereol 2000 80 : 398.
6. García Ortega P, Carrascal Martín M, Herrero Baladrón M, Pérez Martín R. Toxicoderma associated with alendronate. Aten Primaria 2002 29 : 61 62.
7. Kimura M, Kawada A, Murayama Y, Murayama M. Drug eruption due to alendronate sodium hydrate. Contact Derm 2003 48 : 116.
8. Brinkmeier T, Kügler K, Lepoittevin JP, Frosch PJ. Adverse cutaneous drug reaction to alendronate. Contact Derm 2007 57 : 123 125.